Ken Griffin X4 Pharmaceuticals, Inc Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 47,800 shares of XFOR stock, worth $45,888. This represents 0.0% of its overall portfolio holdings.

Number of Shares

47,800

Previous 13,500 254.07%

Holding current value

$45,888

Previous $11,000 500.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.72 - $1.46 $694,951 - $1.41 Million	-965,211 Reduced 55.86%	762,854 $1.06 Million
Q4 2023 Feb 14, 2024	SELL	$0.61 - $0.99 $43,043 - $69,857	-70,563 Reduced 3.92%	1,728,065 $1.45 Million
Q3 2023 Nov 14, 2023	SELL	$1.03 - $2.02 $1.31 Million - $2.58 Million	-1,275,071 Reduced 41.48%	1,798,628 $1.96 Million
Q2 2023 Aug 14, 2023	BUY	$0.82 - $2.49 $2.51 Million - $7.61 Million	3,055,738 Added 17013.18%	3,073,699 $5.96 Million
Q1 2023 May 15, 2023	SELL	$0.8 - $1.22 $741,513 - $1.13 Million	-926,892 Reduced 98.1%	17,961 $15,000

Q4 2022 Feb 14, 2023	BUY	$0.69 - $1.99 $651,948 - $1.88 Million	944,853 New	944,853 $935,000
Q2 2022 Aug 15, 2022	SELL	$0.88 - $1.91 $9,028 - $19,596	-10,260 Reduced 18.48%	45,254 $44,000
Q1 2022 May 16, 2022	SELL	$1.48 - $2.58 $32,835 - $57,239	-22,186 Reduced 28.55%	55,514 $97,000
Q4 2021 Feb 14, 2022	BUY	$1.9 - $5.6 $83,159 - $245,100	43,768 Added 128.99%	77,700 $177,000
Q3 2021 Nov 15, 2021	SELL	$4.53 - $6.45 $59,528 - $84,759	-13,141 Reduced 27.92%	33,932 $180,000
Q2 2021 Aug 16, 2021	BUY	$6.49 - $9.56 $305,503 - $450,017	47,073 New	47,073 $305,000
Q2 2020 Aug 14, 2020	SELL	$7.98 - $10.44 $92,583 - $121,124	-11,602 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$6.03 - $11.01 $69,960 - $127,738	11,602 New	11,602 $116,000

Others Institutions Holding XFOR

# of Institutions

106

Shares Held

103M

Call Options Held

206K

Put Options Held

291K

View Full List

About X4 Pharmaceuticals, Inc

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $65.9M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

More about XFOR

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account